Skip to content

LONA LONA Operating lease right-of-use asset amortization

Operating lease right-of-use asset amortization at other companies

Arvinas logo
ArvinasARVN
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
Immunome logo
ImmunomeIMNM
Arcus Biosciences logo
Arcus BiosciencesRCUS
Dogwood Therapeutics logo
Dogwood TherapeuticsDWTX

Other financials

Income statement

See full
Operating income-$17.2M-80.5%
Net income-$32.9M-260%
EPS (diluted)-$1.73+26.1%

Balance sheet

See full
Cash & equivalents$32.8M+24.3%
Total debt$691.0K-38.2%
Total equity$49.3M+32.1%
Total assets$71.6M+64.5%

Cash flow

See full
Operating cash flow-$20.9M-42.5%
CapEx$28.0K-15.2%
Free cash flow-$26.0M+1.1%

Valuation

See full
Market cap$86.33M+223%
Enterprise value$54.18M

Returns & leverage

See full
Return on equity-298.8%-726pp
Debt / equity0.0×
Current ratio10.4×+3.1×

Where this comes from

Reported directly by LONA in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.

The official record: LONA’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about LONA's operating lease right-of-use asset amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LONA's operating lease right-of-use asset amortization?
LONA (LONA) reported operating lease right-of-use asset amortization of $74K in Q1 2026.
How has LONA's operating lease right-of-use asset amortization changed year-over-year?
LONA's operating lease right-of-use asset amortization increased by 13.8% year-over-year, from $65K to $74K.
What is the long-term trend for LONA's operating lease right-of-use asset amortization?
Over 4 years (2021 to 2025), LONA's operating lease right-of-use asset amortization has grown at a 15.2% compound annual growth rate (CAGR), from $155K to $273K.